Shenzhen S.E.
06:00:00 2024-05-06 pm EDT
5-day change
1st Jan Change
221.7
CNY
-0.55%
+3.23%
+5.47%
Huons Bio Pharma Co., Ltd. announced that it has received KRW 101.8984 billion in funding from Imeik Technology Development Co.,Ltd.
On September 16, 2021, Huons Bio Pharma Co., Ltd. closed the transaction.
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 24
CI
Imeik Technology Development's Profit Rises 47% on Higher Revenue
Mar. 20
MT
Imeik Technology Development Co.,Ltd. Proposes Final Dividend for the Year 2023
Mar. 19
CI
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 19
CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023.
Dec. 08
CI
Imeik Technology Development Co.,Ltd.'s Equity Buyback announced on June 12, 2023, has closed with 1,165,874 shares, representing 0.54% for CNY 399.69 million.
Dec. 06
CI
QL Biopharmaceutical announced that it has received CNY 200 million in funding from BlueRun Investment Consulting Co., Ltd., Imeik Technology Development Co.,Ltd., China-US Green Fund Management Co., Ltd., Shenzhen Jiayuan Capital Management Co., Ltd., Chengdu Science and Technology Innovation Investment Group Co., Ltd., Shanghai Jincheng Equity Investment Fund Management Co., Ltd. and other investors
Nov. 26
CI
Imeik Technology Wins Exclusive Rights to Distribute Jeisys’ Aesthetic Equipment in China
Nov. 09
MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-24
CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023.
23-10-18
CI
Imeik Technology Development Co.,Ltd. Approves Cash Distribution for the First Half of 2023, Payable on 23 October 2023
23-09-14
CI
Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023
23-08-25
CI
Imeik Technology Development's Profit Jumps 65.7% in H1
23-08-25
MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-24
CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023.
23-07-03
CI
Imeik Technology Development Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares.
23-06-12
CI
Imeik Technology Development Co.,Ltd. authorizes a Buyback Plan.
23-06-11
CI
Imeik Technology Development Co.,Ltd. Declares 2022 Final Profit Distribution, Payable on 15 May 2023
23-05-08
CI
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-25
CI
Imeik Technology Development Co.,Ltd. Proposes Final Cash Dividend for 2022
23-03-09
CI
Imeik Technology’s Profit Jumps 32% as Revenue Rises 34% in 2022
23-03-08
MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-08
CI
Imeik Technology Development Co.,Ltd. Approves Director Appointments
22-11-18
CI
Imeik Technology’s Profit Jumps 42% as Revenue Rises 55% in Q3
22-10-26
MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Imeik Technology Development Co Ltd is a China-based company mainly engaged in the research and development, production and sales of biomedical materials. The Company focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The Company has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The Company's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The Company mainly conducts its businesses in the China market.
More about the company
Last Close Price
221.7
CNY
Average target price
315.9
CNY
Spread / Average Target
+42.45%
Consensus
1st Jan change
Capi.
+5.47% 9.24B +10.91% 127B -7.48% 10.91B +20.74% 7.44B +35.84% 5.44B +8.28% 3.44B -6.75% 2.87B -4.71% 2.25B -0.04% 2.23B -20.97% 1.84B
Medical Devices & Implants
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. 
